Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID‐19 patients: A systematic review and meta‐analysis

Abstract

Intravenous immunoglobulin (IVIg) therapy has been suggested as a potential treatment option for hospitalised COVID‐19 patients. The aim of this systematic review and meta‐analysis was to investigate the potential impact of IVIg on mortality and length of hospitalisation in adult COVID‐19 patients. PubMed, Scopus, Web of Science and medRxiv were searched in the week of 20.12.2021 for English language, prospective trials, and retrospective studies with control groups, reporting on the use of intravenous immunoglobulin therapy in adult hospitalised COVID‐19 patients. Exclusion criteria were: studies evaluating the use of IVIg in paediatric COVID‐19 cases, trials using convalescent anti‐SARS‐CoV‐2 plasma or immunoglobulins derived from convalescent anti‐SARS‐CoV‐2 plasma. A random effects meta‐analysis with subgroup analyses regarding study design and patient disease severity according to WHO criteria was also performed. A total of 13 studies were included, of which 6 were prospective, on a total of 2313 (IVIg = 1104, control = 1209) patient outcomes. Meta‐analysis results indicated that IVIg therapy had no statistically significant effect on mortality (RR 0.91 [0.59; 1.39], p = 0.65, I 2 = 69% [46%; 83%]) or length of hospital stay (MD 0.51 [−2.80; 3.81], p = 0.76, I 2 = 96% [94%; 98%]). Subgroup analyses indicated no statistically significant impact on either outcome, but prospective studies' results suggested that IVIg may increase the length of hospitalisation in the severe COVID‐19 patient group (MD 2.66 [1.43; 3.90], p < 0.01, I 2 = 0% [0%; >90%]). The results of this meta‐analysis do not support use of IVIg in hospitalised adult COVID‐19 patients.

Innate and adaptive immunity to SARS-CoV-2 and predisposing factors

“…Other immunotherapies, such as convalescent plasma therapy ( 125 ), intravenous immunoglobulin (IVIG) therapy ( 126 ), mesenchymal stem cells (MSCs) therapy, are also under investigation for the treatment of COVID-19 ( 127 ). Moreover, the efficacy of these therapies against Omicron has not yet been proven and more clinical results are required to draw conclusions.…”

SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges

“…IVIG has carved its place in medical therapeutics, frequently employed in the treatment of inflammatory diseases, immunodeficiency, and severe infections. Its efficacy has been particularly pronounced in patients with primary and secondary immunodeficiencies (PID/SID), exhibiting promising results in clinical settings for formidable adversaries such as SARS and MERS 82–84 …”

Symmetrical peripheral gangrene: potential mechanisms and therapeutic approaches in severe COVID-19

“…The efficacy of IVIG treatment in managing COVID-19 is still a matter of debate. The outcomes of a meta-analysis suggested that IVIg treatment did not have a discernible impact on either the death rate or the duration of hospitalization ( 145 ). While other study showed that IVIG might decrease the death rate in comparison to the control group in severely ill COVID-19 individuals ( 146 ).…”